Immutep's EFTISARC-NEO trial shows 51.5% tumour hyalinization/fibrosis in soft tissue sarcoma.

Immutep's EFTISARC-NEO trial reports positive results for eftilagimod alfa (efti) in treating soft tissue sarcoma, with 51.5% tumor hyalinization/fibrosis across subtypes, including rare and aggressive tumors. Early translational data shows significant immune system activation, with increases in cytokines and chemokines. High levels of key immune proteins, such as interferon-gamma, correlate with pathologic responses and potentially improved survival rates.